Latest Intelligence in Asia-Pacific

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Yet another worry for Indian offshoring companies

It was recently reported that various problems with the Indian outsourcing industry are forcing UK and European firms to look elsewhere for their offshore provision. The issues cited include big wage rises, skills shortages, and incidents around data security. Such problems threaten to topple India's leading offshoring position, and come as rivals are growing ever stronger.

Published By Datamonitor
06 Dec 2006
CommentWire
CommentWire

Yamanouchi/Fujisawa: still some way from world domination

The relatively small size of Japanese pharma players means that independent overseas growth can only take them so far, with international subsidiaries lacking the scale to promote a blockbuster drug. The tie up of Yamanouchi and Fujisawa represents the first step towards a global mega-player, but further partnerships will be essential to enter the top tier of global pharma companies.

Published By Datamonitor
25 Feb 2004
CommentWire
CommentWire

Yamanouchi / Fujisawa: a stellar future

Yamanouchi [4503.TO] and Fujisawa [4511.TO] have revealed that their post-merger company will be known as Astellas. The combined company is expected to become Japan's largest pharmaceutical company, with cardiovascular and AIID products expected to drive growth in the medium term. Although Astellas will face stiff competition, it should prove a good move for both firms.

Published By Datamonitor
26 May 2004
CommentWire
CommentWire

Yakult: targeting US demand for functional health, convenience

Yakult, the Japanese probiotic yogurt drink, is receiving its first launch in the US. Previously only a niche item, Yakult stands to benefit from the increasing maturity in US consumers' desires for credible, convenient nutraceutical solutions.

Published By Datamonitor
27 Sep 2007
CommentWire
CommentWire

Yahoo!/HSBC: PayDirect from New York to Hong Kong

Published By Datamonitor
31 Jul 2001
Expert View
Expert View

Xigris: Lilly's sepsis flop misses out

Eli Lilly's Xigris sales have proved disappointing, for the year-to-date period ending February 28 2002 sales reached just $14 million, bringing total sales to $35 million since the drug's launch in late November 2001. Industry analysts had predicted sales of between $300 and $500 million in 2002, but this now seems unrealistic, so where did it all go wrong?

Published By Datamonitor
22 Mar 2002
Expert View
Expert View

Xarelto data raise questions at the 2010 American Heart Association Scientific Sessions

Results from the ROCKET-AF trial of Xarelto in stroke prevention in atrial fibrillation have been presented at this year's Scientific Sessions of the American Heart Association. While positive, the data show that Xarelto has by no means outperformed Pradaxa. Clinicians may start to see the two drugs as complementary alternatives, based on their respective performance in various subgroups.

Published By Datamonitor
16 Nov 2010
CommentWire
CommentWire

Wyeth: Big Pharma continues its shopping spree

The current economic environment has paved the way for leading pharmaceutical firms to sweep in and buy up smaller players, highlighted by Wyeth's potential acquisition of Crucell and Merck & Co's strategy to aggressively look for targets in 2009. An increasing number of pharmaceutical majors are likely to use this approach to strengthen their biologic portfolios and access novel pipeline drugs.

Published By Datamonitor
09 Jan 2009
CommentWire
CommentWire

Wrigley: profits and expansion

World gum leader Wrigley [WWY] has started 2004 with strong sales and volume growth across the globe. With plans ramping up for a product launch in Singapore later this year, all eyes will be on the campaign Wrigley puts forward to encourage socially responsible gum use and disposal.

Published By Datamonitor
29 Apr 2004
CommentWire
CommentWire

Wrigley: introducing itself to the chocolate market

The purchase of an 80% stake in premium chocolate company A. Korkunov will allow Wrigley, which already operates in Russia, to form effective synergies with the company, through leveraging existing distribution networks, and enable it to capitalize on the growing disposable income of the country's burgeoning middle class. The move will also allow it to branch out into chocolate confectionery.

Published By Datamonitor
24 Jan 2007

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.